Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) PT at $187.72

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned a consensus rating of “Moderate Buy” from the eighteen research firms that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $187.72.

SRPT has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $128.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Robert W. Baird boosted their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, June 21st. Barclays increased their price target on shares of Sarepta Therapeutics from $185.00 to $226.00 and gave the company an “overweight” rating in a research note on Friday, June 21st. Needham & Company LLC reiterated a “buy” rating and issued a $235.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, June 27th. Finally, Royal Bank of Canada boosted their price target on Sarepta Therapeutics from $142.00 to $182.00 and gave the stock a “sector perform” rating in a research report on Friday, June 21st.

Insider Activity

In related news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the completion of the transaction, the executive vice president now directly owns 17,129 shares in the company, valued at approximately $2,768,217.69. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Bilal Arif sold 7,859 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the transaction, the insider now owns 21,261 shares in the company, valued at approximately $3,467,243.88. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the sale, the executive vice president now directly owns 17,129 shares in the company, valued at $2,768,217.69. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,451 shares of company stock worth $8,086,386. Corporate insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently modified their holdings of SRPT. Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after buying an additional 243,180 shares during the period. Capital International Investors increased its position in shares of Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after buying an additional 76,032 shares during the period. Avoro Capital Advisors LLC raised its stake in Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after buying an additional 319,444 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Sarepta Therapeutics by 5.6% in the 4th quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock valued at $398,025,000 after purchasing an additional 217,810 shares during the period. Finally, Farallon Capital Management LLC grew its stake in Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $152.11 on Wednesday. The company has a 50 day moving average price of $134.92 and a two-hundred day moving average price of $126.35. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. The company has a market capitalization of $14.38 billion, a PE ratio of 1,382.82 and a beta of 0.89. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.84. The business had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm’s revenue was up 63.1% compared to the same quarter last year. During the same quarter last year, the business posted ($1.44) EPS. Analysts forecast that Sarepta Therapeutics will post 3.76 earnings per share for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.